New stock news | Health Guardian's Hong Kong IPO prospectus invalid with the world's richest portfolio of HPV vaccine products.

Beijing Kang Le Wei Shi Biotechnology Co., Ltd. (referred to as "Kang Le Wei Shi", North Trading Exchange Code: 833575.BJ) submitted its Hong Kong IPO prospectus on January 29, 2024, which was valid for 6 months and expired on July 29. CITIC SEC and CICC International acted as its joint sponsors when submitting the application. According to the prospectus on January 29, Kang Le Wei Shi is a Chinese clinical-stage vaccine developer with the most comprehensive HPV vaccine product portfolio globally, transitioning from biotechnology research and development to commercialization. The company's three HPV vaccine combinations have high commercial visibility, leading the industry in meeting the needs of different populations for different services. The company's close-to-commercialization trivalent HPV candidate vaccine is the core product, designed to protect East Asian women, and is expected to submit a BLA in China by the end of 2024. The company's Phase III nonavalent HPV candidate vaccine is another core product, expected to be one of the first domestically produced nonavalent HPV candidate vaccines approved for women, with plans to submit a BLA in China in 2025, and is also China's first domestically produced nonavalent HPV candidate vaccine to start critical efficacy trials for men. Financially, as of September 30, 2022 and for the nine months ending on September 30, 2023, Kang Le Wei Shi recorded revenues of approximately 888,000 RMB and 1.601 million RMB respectively; during the same period, the annual losses were approximately 2.11 billion RMB and 2.25 billion RMB respectively.